

Forward together with innovation: The why, what and how of tackling the Implementation Gap for healthcare in different regions

Room Las Arenas IV, Hotel Porta Fira
Pl. d'Europa, 45, 08908 L'Hospitalet de Llobregat, Barcelona, Spain

Saturday, Sept 14th, 2024
13:45 – 17:00 CEST

Overview

Successful development and deployment of healthcare innovation depends on a policy framework in which countries would find it easier to reach consistent decisions and to provide clearer funding arrangements, thus boosting access and continued development.

The renewed attention to disparities in health care and access across different regions, is also driving new assessments of obstacles and new pursuits of solutions and promoting greater networking and collaboration among cancer institutions.

But nothing will happen by accident. Constructive change to the health care context could ensure better use of the potential offered by new technologies in testing, in diagnosis and in treatment of cancer, through development and use of biomarkers and the advanced treatments.

But this will result only from vigorous debate among all stakeholders, and agreement on recommendations of a technical and political nature that will result in a better deal for patients and a more sustainable approach to healthcare.

Target Audience

Attendees will be drawn from key stakeholders from the community whose interaction will create a cross-sectoral, highly relevant and dynamic discussion forum. These participants will include healthcare professionals, decision makers, patient organisations, and umbrella organizations representing interest groups and associations actively engaged in the field of Personalised Medicine. Each session will comprise panel discussions as well as Q&A sessions to allow best possible involvement of all participants

Expected outcomes: It is absolutely clear that it is necessary to formulate a personalised healthcare-centred strategy involving decision makers and regulators in the arena of public health, to enable the EU and Member States to contribute to integrating personalised medicine into clinical practice while enabling much-greater access for patients. In order to provide a clear focus and to devote sufficient space to analysis, discussions during the conference will concentrate on how

- to assess and address obstacles to the integration of personalised medicine into Europe's healthcare systems
- to identify best practices and their added value
- to outline the potential priority areas

Moderator: D. Horgan, EAPM Executive Director

12:45 - 13:45 Registration, coffee, networking

13:30 – 13.45	Setting the Scene
---------------	--------------------------

Denis Horgan, EAPM Executive Director

13:45 - 15:00	Regions
---------------	----------------

Asia: **Janice Tsang (Dr.)**, *Specialist in Medical Oncology, Hon. Clinical Assistant Professor, Li Ka Shing Faculty of Medicine, The University of Hong Kong*

Latin America: **Rodrigo Dienstmann**, *Medical Director, Oncoclínicas Precision Medicine and Big Data Initiatives, São Paulo, Brazil; Researcher, Oncology Data Science Group, Vall d´Hebron Institute of Oncology, Barcelona, Spain*

Patients: **Zorana Maravic**, *Director of Operations, Digestive Cancers Europe*

Africa: **Jackson Orem**, *Medical Oncologist, Director, Uganda Cancer Institute Senior Consultant in Oncology, Uganda Ministry of Health, Faculty, Makerere University and Fred Hutchinson Cancer Research Center*

Middle East/North Africa: **Hesham ElGhazaly**, *Professor of clinical Oncology, Ain Shams University, Egypt & member of the IARC/WHO Scientific Council*

North America: **Vivek Subbiah, M.D.**, *Chief, Early-Phase Drug Development, Sarah Cannon Research Institute (SCRI)*

Discussion

15:00 - 16:15	Prioritization: Disease Focused Session
---------------	--

Setting the Scene: Cancer Mission: **Christine Chomienne**, *Vice-Chair of the Horizon Europe Cancer Mission Board at the European Commission*

Breast: **Fatima Cardoso MD**, *FESMO, Director Breast Unit, Champalimaud Clinical Center, President, ABC Global Alliance, Lisbon, Portugal*

GI Cancers: **Naureen Starling**, *The Royal Marsden; The Royal Marsden NHS Foundation Trust; Institute of Cancer Research, London, UK*

Sarcoma: **Paolo G. Casali MD**, *Director of the Medical Oncology Unit 2 at the Istituto Nazionale Tumori, Milan, Italy*

Melanoma: **Piotr Rutkowski** is *Professor of Surgical Oncology at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland*

Discussion

16:15- 17:15

Translational Research: **Lillian Siu**, *Professor, University of Toronto*

Comprehensive cancer centers: **Josep Tabernero**, *Head of the Medical Oncology Department at the Vall d'Hebron Barcelona Hospital Campus, and Director of the Vall d'Hebron Institute of Oncology (VHIO)*

Liquid Biopsy: **Christian Rolfo MD, PhD**, *director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center*

Patient: **Zorana Maravic**, *CEO, Digestive Cancers Europe*

Discussion

17:15 - 17:30 **Concluding Session: Role of the EU and Member States**

Vivek Subbiah, M.D., *Chief, Early-Phase Drug Development, Sarah Cannon Research Institute (SCRI)*

Denis Horgan, *EAPM Executive Director*